Cyclophosphamide
EBV-Related Gastric Carcinoma
Viracta Therapeutics, Inc.Small moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the EBV-Related Gastric Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Epirubicin Viracta Therapeutics, Inc. | Phase 1 | CC |
Pembrolizumab Viracta Therapeutics, Inc. | Phase 1 | CC |
Valganciclovir Viracta Therapeutics, Inc. | Phase 1 | CC |
Nanatinostat Viracta Therapeutics, Inc. | Phase 1 | C |
Same molecule, other indications
Cyclophosphamide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →